Long-Term Investors Should Consider Buying the Dips in Marrone Bio Innovations Inc. [MBII] Stock

Marrone Bio Innovations Inc. [MBII] shares are up more than 6.09% this year and recently increased 0.04% or $0.05 to settle at $1.22. MBII has a short ratio of 13.78. This implies that the market is currently less bullish on the outlook for MBII.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


On 9, November 2020, Marrone Bio Innovations, Inc. Reports Third-Quarter 2020 Financial Results. According to news published on Yahoo Finance, Expansion in international and seed treatment markets led revenue growth and gross margin improvement.

Analyst Birdseye View:

The most recent analyst activity for Marrone Bio Innovations Inc. [NASDAQ:MBII] stock was on March 16, 2016, when it was Initiated with a Buy rating from Rodman & Renshaw, which also raised its 12-month price target on the stock to $3.50. On May 20, 2015, Jefferies Downgrade a Hold rating. On September 04, 2014, Stifel Reiterated a Buy rating and decreased its price target from $16 to $10. On August 08, 2014, Robert W. Baird Downgrade a Neutral rating and decreased its price target to $12. On June 30, 2014, Robert W. Baird Initiated an Outperform rating and boosted its amount on this stock to $15. On August 27, 2013, Stifel Initiated a Buy rating and boosted its target amount on this stock to $17.

In the past 52 weeks of trading, this stock has oscillated between a low of $0.61 and a peak of $1.50. Right now, according to Wall Street analyst the average 12-month amount target is $1.99. At the most recent market close, shares of Marrone Bio Innovations Inc. [NASDAQ:MBII] were valued at $1.22. According to the average price forecast, investors can expect a potential return of 0.5%.


Marrone Bio Innovations Inc. [NASDAQ:MBII] most recently reported quarterly sales of 8.83 billion, which represented growth of 25.70%. This publicly-traded organization’s revenue is $220,850 per employee, while its income is -$279,511 per employee. This company’s Gross Margin is currently 58.10%, its Operating Margin is -56.80%, its Pretax Margin is -126.56, and its Net Margin is -126.56. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -62.33, -203.73, -50.75 and -94.44 respectively.

The Principal structure of this organization shows its whole liability to whole principal at 54.24 and the whole liability to whole assets at 38.41. It shows enduring liability to the whole principal at 44.90 and enduring liability to assets at 0.32 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 1.1633 points at 1st support level, the second support level is making up to 1.1067. But as of 1st resistance point, this stock is sitting at 1.2633 and at 1.3067 for 2nd resistance point.

Marrone Bio Innovations Inc. [MBII] reported its earnings at -$0.04 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.03/share signifying the difference of -0.01 and -33.30% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.03 calling estimates for -$0.06/share with the difference of 0.03 depicting the surprise of 50.00%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for Marrone Bio Innovations Inc. [NASDAQ:MBII] is 1.00. Likewise, the Quick ratio is also the same, showing Cash ratio at 0.30. Now if looking for a valuation of this stock’s amount to sales ratio it’s 4.06 and it’s amount to book ratio is 5.98.